- Previous Close
2,587.00 - Open
2,542.00 - Bid 2,525.00 x --
- Ask 2,548.00 x --
- Day's Range
2,496.00 - 2,573.00 - 52 Week Range
2,488.00 - 3,395.00 - Volume
170,300 - Avg. Volume
122,775 - Market Cap (intraday)
124.545B - Beta (5Y Monthly) -0.23
- PE Ratio (TTM)
6.61 - EPS (TTM)
383.04 - Earnings Date May 12, 2025 - May 16, 2025
- Forward Dividend & Yield 80.00 (3.09%)
- Ex-Dividend Date Mar 28, 2025
- 1y Target Est
3,860.00
Towa Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells ethical drugs, active pharmaceutical ingredients, and intermediates in Japan. The company provides its products in the therapeutic areas of digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products. It also offers IT service related to healthcare; and disease risk testing services. In addition, the company is involved with research and development of diagnostic drugs; and planning, development and OEM manufacturing of health food, pharmaceuticals, general food and other products. The company was founded in 1951 and is headquartered in Osaka, Japan.
www.towayakuhin.co.jp4,588
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: 4553.T
View MorePerformance Overview: 4553.T
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4553.T
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4553.T
View MoreValuation Measures
Market Cap
124.54B
Enterprise Value
318.77B
Trailing P/E
6.46
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.49
Price/Book (mrq)
0.74
Enterprise Value/Revenue
1.26
Enterprise Value/EBITDA
10.47
Financial Highlights
Profitability and Income Statement
Profit Margin
7.61%
Return on Assets (ttm)
3.16%
Return on Equity (ttm)
12.13%
Revenue (ttm)
253.35B
Net Income Avi to Common (ttm)
19.28B
Diluted EPS (ttm)
383.04
Balance Sheet and Cash Flow
Total Cash (mrq)
29.25B
Total Debt/Equity (mrq)
132.22%
Levered Free Cash Flow (ttm)
--